Stockscreener 앱 받기
1.08
12.20%
-0.15
시장 영업 전:
1.14
0.06
+5.56%
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
What is Allogene Therapeutics Inc. company’s growth strategyBuild wealth steadily with proven investment strategies - jammulinksnews.com
What are the technical indicators suggesting about Allogene Therapeutics Inc.High-yield growth strategies - jammulinksnews.com
When is Allogene Therapeutics Inc. stock expected to show significant growthInvest confidently with market-leading analysis - jammulinksnews.com
How does Allogene Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - jammulinksnews.com
Is it the right time to buy Allogene Therapeutics Inc. stockJaw-dropping returns - jammulinksnews.com
Is Allogene Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - jammulinksnews.com
What drives Allogene Therapeutics Inc. stock priceStrong return on assets - jammulinksnews.com
What are Allogene Therapeutics Inc. company’s key revenue driversUnstoppable profit momentum - jammulinksnews.com
How many analysts rate Allogene Therapeutics Inc. as a “Buy”Access daily stock market expert updates - jammulinksnews.com
What is the dividend policy of Allogene Therapeutics Inc. stockGet real-time alerts on high-potential stocks - jammulinksnews.com
What are the latest earnings results for Allogene Therapeutics Inc.Jaw-dropping returns - jammulinksnews.com
How volatile is Allogene Therapeutics Inc. stock compared to the marketBeginner Investor Report With Low Risk - jammulinksnews.com
Allogene Therapeutics Faces Market Volatility Amid Financial Challenges - StocksToTrade
Allogene Resets Clinical Course After Patient Death In Lymphoma StudyAllogene Therapeutics (NASDAQ:ALLO) - Benzinga
Regeneron cancer bispecific rejected again; Allogene discloses trial death - BioPharma Dive
Allogene Therapeutics updates ALPHA3 trial protocol following safety event By Investing.com - Investing.com India
Allogene Therapeutics updates ALPHA3 trial protocol following safety event - Investing.com
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event - TipRanks
RENT Form 144: Insider plans to sell 262 shares worth $1.49k | ALLO SEC FilingForm 8-K - Stock Titan
Allogene Therapeutics Announces Selection of Standard FC Lymphodepletion Regimen in ALPHA3 Study Following Consultation with FDA and Safety Board - Quiver Quantitative
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - The Manila Times
Allogene says lymphodepletion drug caused patient death, changes CAR-T study design - Endpoints News
Allogene Therapeutics shares rise 2.33% premarket after Robbins LLP class action filing. - AInvest
Understanding Allogene Therapeutics Inc.’s price movementCommunity Entry Consensus Trade Ideas Shared - metal.it
Allogene Therapeutics Inc. Trading Near Value Zone — Recovery AheadWatchlist for Low Risk High Return Stocks Updated - metal.it
RSI Crosses Above 30 for Allogene Therapeutics Inc. — Reversal in SightLow Volatility Stable Growth Picks Rank High - metal.it
Published on: 2025-07-29 12:47:04 - metal.it
CAR-T Cell Therapy Market is projected to grow to US$ 20.4 billion - openPR.com
Allogene Therapeutics Inc. Forms Bullish Flag — Upside AheadLow Drawdown Real Time Trading Tips Shared - metal.it
What is the risk reward ratio of investing in Allogene Therapeutics Inc. stockBest Dividend Forecasts To Watch Now - jammulinksnews.com
Does Allogene Therapeutics Inc. stock perform well during market downturnsPre Market Ideas For Beginners - jammulinksnews.com
How does Allogene Therapeutics Inc. generate profit in a changing economyAchieve breakthrough financial results today - jammulinksnews.com
What institutional investors are buying Allogene Therapeutics Inc. stockBuild a diversified portfolio for steady growth - jammulinksnews.com
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update - ADVFN Brasil
Allogene’s ALLO-329: A New Frontier in Autoimmune Disease Treatment - TipRanks
Is Allogene Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - PrintWeekIndia
Global Allogeneic Cell Therapy Market to grow at 25% CAGR on rising demand and trials by 2030 - PharmiWeb.com
Is Allogene Therapeutics Inc. stock a good hedge against inflationConsistent triple returns - jammulinksnews.com
Allogene Therapeutics Inc. Stock Analysis and ForecastExplosive trading growth - PrintWeekIndia
Multiple Insiders Sold Allogene Therapeutics Shares Presenting Weak Signs For Investors - 富途牛牛
What analysts say about Allogene Therapeutics Inc. stockRapid return acceleration - Autocar Professional
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
0.93%
0.15%
자본화:
|
볼륨(24시간):